IDH1 mutation analysis in low cellularity specimen: A limitation of diagnostic accuracy and a proposal for the diagnostic procedure

Pathology Research and Practice

Volumn 209, Issue 5, 2013, Pages 284-290

  Choi, Junjeong ^a,b   Lee, Eun Young ^c   Shin, Kyung Jin ^c   Minn, Yang Ki ^d   Kim, Jieun ^c   Kim, Se Hoon ^c  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Hallym University College of Medicine   (South Korea)

Author keywords

Direct sequencing; Gliomas; Immunohistochemistry; Isocitrate dehydrogenase (IDH) 1 mutation; Multiplex PCR with single base extension; Peptide nucleic acid clamping

Indexed keywords

DNA; ISOCITRATE DEHYDROGENASE 1;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIRECT SEQUENCING; FEMALE; GENE MUTATION; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; OLIGODENDROGLIOMA; PEPTIDE NUCLEIC ACID CLAMPING; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DIAGNOSTIC ERRORS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878451058     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.02.010     Document Type: Article

References (31)

1. Lai A., Kharbanda S., Pope W.B., Tran A., Solis O.E., Peale F., Forrest W.F., Pujara K., Carrillo J.A., Pandita A., Ellingson B.M., Bowers C.W., Soriano R.H., Schmidt N.O., Mohan S., Yong W.H., Seshagiri S., Modrusan Z., Jiang Z., Aldape K.D., Mischel P.S., Liau L.M., Escovedo C.J., Chen W., Nghiemphu P.L., James C.D., Prados M.D., Westphal M., Lamszus K., Cloughesy T., Phillips H.S. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2011, 29:4482-4490.
2. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N., Cancer Genome Atlas Research N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
3. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., Verhaak R.G., Hoadley K.A., Hayes D.N., Perou C.M., Schmidt H.K., Ding L., Wilson R.K., Van Den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L.M., Buckley J., Herman J.G., Baylin S.B., Laird P.W., Aldape K., Cancer Genome Atlas Research N. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
4. Hartmann C., Hentschel B., Wick W., Capper D., Felsberg J., Simon M., Westphal M., Schackert G., Meyermann R., Pietsch T., Reifenberger G., Weller M., Loeffler M., von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010, 120:707-718.
5. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
6. Yip S., Iafrate A.J., Louis D.N. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J. Neuropathol. Exp. Neurol. 2008, 67:1-15.
7. Riemenschneider M.J., Jeuken J.W., Wesseling P., Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010, 120:567-584.
8. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J.P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J.C., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O., Reifenberger G., von Deimling A., Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2009, 27:5743-5750.
9. Capper D., Weissert S., Balss J., Habel A., Meyer J., Jager D., Ackermann U., Tessmer C., Korshunov A., Zentgraf H., Hartmann C., von Deimling A. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010, 20:245-254.
10. Capper D., Zentgraf H., Balss J., Hartmann C., von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009, 118:599-601.
11. Horbinski C., Kofler J., Kelly L.M., Murdoch G.H., Nikiforova M.N. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J. Neuropathol. Exp. Neurol. 2009, 68:1319-1325.
12. Perizzolo M., Winkfein B., Hui S., Krulicki W., Chan J.A., Demetrick D.J. IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension. Brain Pathol. 2012, 22:619-624.
13. Loussouarn D., Le Loupp A.G., Frenel J.S., Leclair F., Von Deimling A., Aumont M., Martin S., Campone M., Denis M.G. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int. J. Oncol. 2012, 40:2058-2062.
14. Felsberg J., Wolter M., Seul H., Friedensdorf B., Goppert M., Sabel M.C., Reifenberger G. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010, 119:501-507.
15. Horbinski C., Kelly L., Nikiforov Y.E., Durso M.B., Nikiforova M.N. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J. Mol. Diagn. 2010, 12:487-492.
16. Meyer J., Pusch S., Balss J., Capper D., Mueller W., Christians A., Hartmann C., von Deimling A. PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol. 2010, 20:298-300.
17. Setty P., Hammes J., Rothamel T., Vladimirova V., Kramm C.M., Pietsch T., Waha A. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J. Mol. Diagn. 2010, 12:750-756.
18. Preusser M., Wohrer A., Stary S., Hoftberger R., Streubel B., Hainfellner J.A. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J. Neuropathol. Exp. Neurol. 2011, 70:715-723.
19. Takano S., Tian W., Matsuda M., Yamamoto T., Ishikawa E., Kaneko M.K., Yamazaki K., Kato Y., Matsumura A. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011, 28:115-123.
20. Miyazawa H., Tanaka T., Nagai Y., Matsuoka M., Huqun, Sutani A., Udagawa K., Zhang J., Hirama T., Murayama Y., Koyama N., Ikebuchi K., Nagata M., Kanazawa M., Nukiwa T., Takenoshita S., Kobayashi K., Hagiwara K. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 2008, 99:595-600.
21. Leisenring W., Pepe M.S., Longton G. A marginal regression modelling framework for evaluating medical diagnostic tests. Stat. Med. 1997, 16:1263-1281.
22. Barnhart H.X., Williamson J.M. Weighted least-squares approach for comparing correlated kappa. Biometrics 2002, 58:1012-1019.
23. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
24. Camelo-Piragua S., Jansen M., Ganguly A., Kim J.C., Cosper A.K., Dias-Santagata D., Nutt C.L., Iafrate A.J., Louis D.N. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J. Neuropathol. Exp. Neurol. 2011, 70:110-115.
25. Ogino S., Kawasaki T., Brahmandam M., Yan L., Cantor M., Namgyal C., Mino-Kenudson M., Lauwers G.Y., Loda M., Fuchs C.S. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J. Mol. Diagn. 2005, 7:413-421.
26. Hancer V.S., Buyukdogan M., Turkmen I., Bassullu N., Altug T., Diz-Kucukkaya R., Bulbul-Dogusoy G., Demir G. Comparison of KRAS mutation tests in colorectal cancer patients. Genet. Testing Mol. Biomark. 2011, 15:831-834.
27. Heper A.O., Erden E., Savas A., Ceyhan K., Erden I., Akyar S., Kanpolat Y. An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: a prospective clinicopathologic study. Surg. Neurol. 2005, 64(Suppl. 2):S82-S88.
28. Samadani U., Stein S., Moonis G., Sonnad S.S., Bonura P., Judy K.D. Stereotactic biopsy of brain stem masses: decision analysis and literature review. Surg. Neurol. 2006, 66:484-490. (discussion 491).
29. M.S. Pepe, The statistical evaluation of medical tests for classification and prediction, New York, 2003.
30. K. Meier, Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests, in: F.D.A. U.S. Department of Health and Human Services, Center for Devices and Radiological Health, Diagnostic Devices Branch, Division of Biostatistics. Office of Surveillance and Biometrics, 2007.
31. Reitsma J.B., Rutjes A.W., Khan K.S., Coomarasamy A., Bossuyt P.M. A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J. Clin. Epidemiol. 2009, 62:797-806.